International Journal of Integrated Research and Practice (IJIRP)

Vol 1, Issue 4, July, 2025, Page: 43-54 ISSN: 3107-5037

# Bacteriophage-Mediated Modulation of the Gut Virome in Antibiotic-Resistant Enterobacteriaceae

**Dr. Anant Sanjayrao Deshpande**
Assistant professor
Department of Zoology
Chintamani College of Science, Pombhurna, Dist. Chandrapur M.S.

## Abstract

The increasing emergence of antibiotics-resistant Enterobacteriaceae is a significant health issue around the world, and it demands new treatment methods instead of typical antimicrobials. Bacteriophages Natural bacterial viral predators are now becoming a viable direct pathogen control tool and can also be used to modulate microbiomes. In this research paper, the author seeks to find out the value of bacteria phage as the alternative to remodel the gut virome and the relief of multidrug-resistant Enterobacteriaceae. We then considered phage host interactions, viral community structure changes, and downstream microbial ecology using in vitro models of gut microbiota as well as live murine infection models. The responses in our experimental groups indicate that specific phage-mediated treatments can lead to large decreases in resistant populations of Enterobacteriaceae with concomitant changes in the entire virome within the gut environment, especially phage distribution and horizontal gene transfer rates. Interestingly, phage killing reduced carriage of plasmid-encoded resistance resistance, and this therefore provided a dual advantage in both reduced bacterial load and limitation of resistance spread. Virome sequencing also exemplified creation of new phage-bacterial steady states, meaning phage therapy has more to it than merely clearing pathogens, but has effects in the realm of altering ecological stability. Critically, microbiota diversity was kept to a great extent with the least interruption in commensal populations of bacterium. These results help identify the therapeutic promise of phages as precision therapeutics to manipulate microbial ecosystems to respond to challenges in antibiotic resistance. This effort has given fundamental answers regarding how phages can alter virome architecture and reservoirs of resistance genes, information that can form the basis of logical strategies in the design of phage-based interventions. Applications of phage therapy in the future can be individualizing phage cocktails and phage-antibiotic combination approaches to resist infections. In sum, weaved genus of bacteriophage virus in the gut or microbiome seems to be a feasible and ecologically friendly approach to the worldwide problem of antibiotic-resistant Enterobacteriaceae.

**Keywords:** Bacteriophage therapy, Gut virome, Antibiotic resistance, Enterobacteriaceae, Microbiome modulation

## Introduction

The worldwide health threat of the current spread of antibiotic-resistant Enterobacteriaceae derailing the viability of traditional treatment procedures and consequently causing an augmented morbidity and mortality. In the gastrointestinal tract, the opportunistic pathogens grow in the conditions of ecological disproportions caused by antibiotics, which also destroys the communities of commensal bacteria and deranges the virome. Of the various components of the virome, bacteriophages have received increased interest as regulators of microbial dynamics on the basis of their selectivity in acting on bacterial populations. Phages are specific host-specific antibiotics, unlike broad-spectrum antibiotics, making it possible to manipulate resistant strains with specificity, and preserve useful microbiota.

Vol 1, Issue 4, July, 2025, Page: 43-54 ISSN: 3107-5037

**Table 1: Representative Phages Targeting Antibiotic-Resistant Enterobacteriaceae**

| Phage Name | Host Bacteria | Genome Type | Notable Features | Clinical/Experimental Use |
|---|---|---|---|---|
| T4-like phages | *Escherichia coli* (ESBL-producing) | dsDNA | High lytic activity | Gut microbiome modulation in mice |
| Klebsiella phage KP34 | *Klebsiella pneumoniae* (carbapenem-resistant) | dsDNA | Broad host range | Compassionate therapy case reports |
| P22 | *Salmonella enterica* | dsDNA | Generalized transduction | Tool for studying virome interactions |
| phiKT | *Enterobacter cloacae* | dsDNA | Temperate phage | Bacteriome–virome balance regulation |

The development of new methodologies in sequencing in recent years has discovered that bacteriophages are not inert components of the gut ecosystem but dynamic control factors that modulate the composition and the work of microbes. They interact with one another in numerous ways more complex than mere bacterial lysis, factors affecting horizontal gene transfer, immune modulation and ultimately the evolutionary path of microbial communities. Phage activity can act as a natural counterweight to overgrowth of pathogens in the case of antibiotic resistant Enterobacteriaceae and suppress resistance determinant transmission. In addition, therapeutic opportunities including the phage-based gut virome regulation exist in the treatment of diseases as the field of phage therapy is reemerging once again due to the depleted antibiotic pipeline.

It is important to gain insight of the mechanisms through which bacteriophages impact the gut virome in resistant Enterobacteriaceae infections to come up with novel interventions. This study aims at investigating the ecological and medical consequences of phage-driven modulation, focusing on the ways of using phage-bacteria interactions to circumvent resistance, reestablish microbial ecology, and introduce a means to improve patient outcomes. With these dynamics clarified, we can possibly discover new methods of combining phage therapy with microbiome bases practices, which would provide long-term solutions to the rising menace of multi drug resistant Enterobacteriaceae.

**Background of the study**

The resistance of Enterobacteriaceae to antibiotics and the challenges of their spread worldwide present a significant challenge in terms of the public health problem, not to mention the fact that such pathogens cause dangerous intestinal and extraintestinal infections that are becoming increasingly resistant to treatment. The traditional antimicrobial drug strategies are quickly becoming non-effective because of increased rate of evolution of resistance genes and their spread by the horizontal gene transfer methodology. Such a disturbing trend has led to the need to find alternative ways of combating multidrug-resistant bacteria in the intestinal environment.

**Table 2: Mechanisms of Bacteriophage-Mediated Gut Virome Modulation**

| Mechanism | Description | Effect on Enterobacteriaceae | Impact on Gut Microbiota |
|---|---|---|---|
| Direct lysis | Phages infect and lyse resistant bacteria | Reduces resistant populations | Shifts microbial balance toward commensals |
| Horizontal gene transfer | Movement of ARGs via transduction | Can disseminate resistance | Alters virome-genome interactions |

Vol 1, Issue 4, July, 2025, Page: 43-54 ISSN: 3107-5037

| Mechanism | Description | Effect on Enterobacteriaceae | Impact on Gut Microbiota |
|---|---|---|---|
| Competitive exclusion | Phages outcompete resistant bacteria | Prevents overgrowth | Stabilizes gut diversity |
| Immune modulation | Phage–immune system interactions | Enhances bacterial clearance | Modulates inflammation |

A potentially interesting method is the utilization of the therapeutic and ecological potential of the bacteria phages aka viruses that specifically infect and lysis the bacteria. Bacteriophages have a host specificity in contrast to broad-spectrum antiobiotics and therefore minimize collateral interference of commensal microbiota. Recently, other reports have indicated that bacteria phages do not only kill pathogenic strains but also can shape the dynamics of the greater virome and microbial community complex. These modulations may change competition among the microbes, restructure resistance gene repositories, and re-establish equilibrium among microbes in the gastrointestinal tract.

The own gut virome, which is comprised of different bacteriophages and eukaryotic viruses, is also highly important in controlling the composition of microbes, immune reactions, and the health of the host in general. Its involvement in antibiotic resistance, as well as pathogen colonization, is not well-characterized, however. There is a growing appreciation of the importance of the effect phage therapy has on the prevailing virome of a patient, which is essential to predict the effect of phage therapy, and prevent undesirable ecological side effects, including the enrichment of resistance genes or destabilization of beneficial bacterial populations.

With these considerations in mind, the concept of bacteriophage-facilitated shaping of the gut virome with respect to antibiotic-resistant Enterobacteriaceae is promising in not only conveying potential therapy but microbial ecology as well. Such investigation not only helps to make the phage-based intervention options but also helps one to understand the gut resistome better, virome-host interactions, and how sustainable intervention can help address the antibiotic resistance crisis.

**Justification**

Antibiotic-resistant Enterobacteriaceae is a worldwide menace to community health because the diseases are accompanied with life-threatening infections that are becoming hard to cure using common approaches. The pace of modern antibiotic development has become extremely slow, whereas bacterial means of resisting the antibiotics enter a period of accelerating evolution. This increasing mismatch calls on a desperate demand of operational alternatives therapeutic strategies and preventive strategies.

One of the directions in solving this challenge is bacteriophages, a natural bacterial predator. In contrast to the broad-spectrum antibiotics, phages demonstrate high specificity, and as a result, there is a possibility to target pathogenic bacteria without causing the significant shifts in the commensal microbiota. This trait is especially important in the intestine, where the balance of microbes is key to the immune system functioning, metabolism, and health.

**Table 3: Antibiotic Resistance Genes (ARGs) and Potential Phage Carriers**

| Resistance Gene | Associated Bacteria | Phage Involvement | Risk to Gut Virome |
|---|---|---|---|
| blaCTX-M | *E. coli* (ESBL) | Rarely phage-encoded | Low but possible spread |
| blaKPC | *K. pneumoniae* | Rare | Potential in nosocomial |

Vol 1, Issue 4, July, 2025, Page: 43-54 ISSN: 3107-5037

| Resistance Gene | Associated Bacteria | Phage Involvement | Risk to Gut Virome |
|---|---|---|---|
| | (carbapenemase) | | settings |
| qnr genes | *Enterobacter cloacae* (quinolone resistance) | Transduction documented | Increased mobility |
| tet(A) | Enteric bacteria | Some phage association | May contribute to tetracycline resistance |

Among the rather poorly studied elements of the microbiome is the gut virome, which is a key factor that regulates the interaction between microbes, but the relationship between such microbiome elements and antimicrobial resistance mechanisms is poorly characterized. To gain valuable insights into both practical effects on bacteria and wider-scale ecological implications in the gut microbiome, it could be useful to study the effects that the bacteriophage therapy has in recasting the virome. Further, elucidating how the phage alters the state of the virome can also provide insight into how the horizontal gene flow of the resistance determinants can be inhibited through these processes, thus alleviating one of the key factors of the antimicrobial resistance spread.

This study is not only justified by the clinical urgency of the development of new methods of fighting multidrug-resistant, Enterobacteriaceae but can contribute to the basic understanding of the phage-virome-hosts relationship. The research will fill in the gap between innovation in therapy and ecological knowledge by involving practical and theoretical contributions that can guide the use of microbiomes in future microbiome-based therapeutic approaches, precision phage therapy, and future research against antibiotic resistance worldwide.

**Objectives of the Study**

1. To investigate the role of bacteriophages in regulating the gut virome and their potential to influence microbial dynamics in the presence of antibiotic-resistant Enterobacteriaceae.
2. To assess the therapeutic potential of bacteriophage application as an alternative or complementary strategy to antibiotics for controlling multidrug-resistant Enterobacteriaceae populations.
3. To evaluate the ecological impact of bacteriophage interventions on gut microbial balance, including effects on commensal bacteria and overall microbial diversity.
4. To determine the mechanisms by which bacteriophages interact with antibiotic-resistant bacterial strains, focusing on lytic activity, horizontal gene transfer, and resistance modulation.
5. To explore the long-term implications of phage therapy on host health, gut virome stability, and the prevention of resistance proliferation.

**Literature Review**

**1. Dynamic individualized ecology of the gut virome:**

The bacteriophage populations are immense but highly personalized and rather stable in individuals, but variable among people in the human gut (Minot et al., 2011; Shkoporov et al., 2019). Initial metagenomic surveys have suggested both that viromes have long term persistence, in some cases spanning months whilst maintaining person-specific patterns, and that they coevolve with their hosts over time within the gut (Reyes et al., 2010; Minot et al., 2011). Later longitudinal studies support the notion of a stable, continuously present, and frequently crAss-like phage-dominated, personal virome, probably driving bacterial community formation and activity (Shkoporov et al., 2019).

Vol 1, Issue 4, July, 2025, Page: 43-54 ISSN: 3107-5037

## 2. Antibiotic disturbance and phage encoded features

The restructuring of bacterial communities results in remodeling associated with the so-called phageome where the accessory genes are enriched with phage encoded accessory genes, which are capable of delivering post-therapeutic evolutionary adaptations (Modi et al., 2013). Some antibiotics have been shown to enhance the yield of lytic phages--so-called phage-antibiotic synergy (PAS)--at suboptimal concentrations, which can raise the rate of phage-mediated bacterial turnover and its associated gene transfer (Comeau et al., 2007). In addition to prominent impacts on lytic events, prophage induction by a wide variety of signals in hosts, microbes, and the environment occurs, moreover, challenging that medication causes prophage induction upsurge in the liberation of temperate phages and their cargoes (Duan et al., 2023).

## 3. Phages, horizontal gene transfer, antibiotic resistance

It is still debated whether gut phages are common vectors of antibiotic resistance genes (ARGs). Analysis of phage DNA fractions in environmental and human sources found β-lactamase and other ARGs and reported the transfer possibilities in some circumstances (Colomer-Lluch et al., 2011a, 2011b; Brown-Jaque et al., 2015, 2018). In contrast, close viromes re-analyses indicate that ARGs are only infrequently found in genuine phage genomes, which indicates that prior indicators may indicate bacterial DNA contamination or generalized transduction and not actual carriage (Enault et al., 2017). Nevertheless, on highly populated environments in the gut, even infrequent transduction by phage may still be some epidemiological consideration when under antibiotic selection (Modi et al., 2013; Brown-Jaque et al., 2015).

## 4. Focal hosts in the gut Enterobacteriaceae

The frequent colonizers of the gut include Enterobacteriaceae (e.g., Escherichia coli and Klebsiella pneumoniae), which also serve as high-profile reservoirs of multidrug resistance in the medical practice. Phages against uropathogenic and ESBL-producing E. coli have the potential to decrease both planktonic burdens and biofilm burdens both in vitro and in a catheter/urine model, with tailoring of cocktails to their hosts augmenting killing of modern isolates (Hammond et al., 2022; Abedon et al., 2024; Palma & Qi, 2024). In the case of K. pneumoniae, an effective phage-mediated suppression and antibiotic synergy in biofilm and in vivo pneumonia models have been demonstrated in vivo and preclinical studies, but the variation in strains and capsules limits the application range of host (Draper et al., 2022; Li et al., 2024; Zhang et al., 2025; Yang et al., 2024).

## 5. Antibiotic selection and phage: synergy and collateral effects

PAS may increase bacterial killing and control the biofilm when phage predation is combined with 2 lactams, quinolones, or any other agent (Comeau et al., 2007; Ryan et al., 2012; Chaudhry et al., 2021). In clinical practice, both case series and compassionate-use cohorts support the idea that adjunctive phage plus antibiotics may enhance the killing of bacteria and outcomes, including in selected Enterobacteriaceae infections (Dedrick et al., 2023; Schooley et al., 2022; Uyttebroek et al., 2022; Jault et al., 2019), albeit with few controlled trials. Remarkably, non-target members of the communities and metabolites can as well be transformed by phage-antibiotic combos, which points out to indirect effects on ecology, which is crucial to keep track (Hsu et al., 2019a, 2019b).

## 6. Interfaces and the ecology of mucosal hosts and phages

Phages are able to bind mucus through Ig-like capsid regions at the points of mucosal contact where they assemble a non-host defense against bacterial colonization, a further axes of phage-mediated control of pathogen interactions in the GI tract (Barr et al., 2013; Barr et al.,

Vol 1, Issue 4, July, 2025, Page: 43-54 ISSN: 3107-5037

2015; Schnitzenbaumer et al., 2022). Phage interactions with mucus could be relevant to dispersal, encounter strengths, and survival with an impact on Enterobacteriaceae colonization resistance and invasion (Barr et al., 2013; Schnitzenbaumer et al., 2022).

**7. Reductionist and in vivo analysis of mechanisms**

Experiments in gnotobiotic mice that involve the addition of lytic phages to specific colonization constructions show that targeted depletion of susceptible bacteria in the community occurs, accompanied by top-down cascades of changes across taxa and metabolites, supporting a top-down control role of phage (Hsu et al., 2019a, 2019b). Such an outcome is also further demonstrated by a recent phage-conditioned mouse model indicating that the result of active phage population pharmacologic depletion can alter antibiotics effect on commensals, which further underscores the bi-directionality of phage actions and antibiotic responses in vivo (Zheng et al., 2025).

**8. Open questions and consequences with respect to antibiotic-resistant Enterobacteriaceae**

Notable gaps include: (i) the actual pattern of and circumstances under which phage-borne ARGs can transfer in human gut; (ii) the impact of prophage induction in antibiotic-treated Enterobacteriaceae with regard to fitness, virulence, and plasmid retention; (iii) the most appropriate design principles to create person-specific, nonresistant phage cocktails, which remain efficacious despite receptor change (capsules, LPS, porins); and (iv) the community level and immunologic outcomes of repeated phage treatment Answering such questions will necessitate paired longitudinal paired longitudinal metagenomics/viromics and culturebased host-range mapping, phylogenetically informative and mechanistically transparent animal models that include current antibiotic regimens and highly controlled clinical trials.

## Material and Methodology

### Research Design

This study employed an experimental laboratory-based design complemented by in vivo validation in murine models. The primary objective was to investigate how bacteriophage therapy influences the composition and dynamics of the gut virome in the presence of antibiotic-resistant *Enterobacteriaceae*. The study followed a controlled comparative approach, consisting of three groups: (i) antibiotic-resistant *Enterobacteriaceae* infection without intervention (control), (ii) bacteriophage administration, and (iii) combined bacteriophage and probiotic intervention. Longitudinal analysis was carried out to assess virome diversity, bacterial abundance, and antimicrobial resistance gene profiles.

### Data Collection Methods

1. **Bacterial Isolation and Resistance Profiling:** Clinical isolates of *Enterobacteriaceae* resistant to third-generation cephalosporins and carbapenems were obtained from microbiology repositories. Resistance profiles were confirmed using Kirby–Bauer disc diffusion and minimum inhibitory concentration (MIC) assays.
2. **Bacteriophage Isolation and Characterization:** Environmental samples (wastewater and fecal filtrates) were screened for bacteriophages targeting the resistant strains. Isolated phages were purified through plaque assays and characterized using electron microscopy and whole-genome sequencing.
3. **Animal Model Experimentation:** Germ-free and conventional C57BL/6 mice were colonized with resistant *Enterobacteriaceae*. Phage suspensions were administered orally, followed by fecal sampling at predefined intervals (days 0, 3, 7, and 14).
4. **Metagenomic Sequencing:** Fecal DNA was extracted, and shotgun metagenomic sequencing was performed to profile viral and bacterial communities. Bioinformatics

Vol 1, Issue 4, July, 2025, Page: 43-54 ISSN: 3107-5037

pipelines (Kraken2, MetaPhlAn, and VirSorter) were used to analyze virome composition and antimicrobial resistance gene carriage.

5. **Statistical Analysis:** Diversity indices (Shannon and Simpson), differential abundance testing, and network analysis were applied. Statistical significance was assessed using ANOVA or Kruskal–Wallis tests, depending on data distribution.

**Inclusion and Exclusion Criteria:**

- **Inclusion Criteria**
  - *Enterobacteriaceae* isolates showing confirmed resistance to at least one major antibiotic class.
  - Mice with successful colonization by resistant strains.
  - Bacteriophages with confirmed lytic activity against target strains.
- **Exclusion Criteria:**
  - Bacterial isolates with incomplete resistance profiles.
  - Phages demonstrating lysogenic or temperate activity.
  - Animal subjects with pre-existing gastrointestinal infections or failure of colonization.

**Ethical Considerations:**

All experimental procedures were conducted in compliance with institutional biosafety and animal ethics regulations. Approval was obtained from the Institutional Animal Care and Use Committee (IACUC). Humane endpoints were defined to minimize animal suffering, and all animals were monitored daily for signs of distress. In vitro experiments involving clinical isolates were carried out in Biosafety Level-2 facilities, with adherence to appropriate waste disposal and decontamination protocols. No human subjects were directly involved; therefore, institutional review board (IRB) approval was not required.

## Results and Discussion

### 1. Bacteriophage Treatment Alters Gut Virome Composition

Metagenomic sequencing revealed significant shifts in virome composition following phage administration. In the treatment group, Enterobacteriaceae-specific phages accounted for a 4.6-fold increase in relative abundance compared with the control group ($p < 0.01$). Concurrently, the relative abundance of non-Enterobacteriaceae phages, particularly those targeting commensal *Bacteroides* spp., remained stable ($p > 0.05$), suggesting targeted modulation.

**Table 4: Relative abundance (%) of major viral taxa before and after phage treatment**

| Viral Taxa | Control (Day 7) | Phage-Treated (Day 7) | Fold Change | p-value |
|---|---|---|---|---|
| Enterobacteriaceae phages | 8.5 ± 1.2 | 39.1 ± 2.5 | ↑4.6x | 0.008 |
| Bacteroides phages | 22.3 ± 3.4 | 23.7 ± 3.6 | NS | 0.611 |
| Lactobacillus phages | 14.7 ± 2.1 | 16.1 ± 1.9 | NS | 0.420 |
| Unclassified phages | 54.5 ± 4.9 | 21.1 ± 2.8 | ↓2.6x | 0.012 |

### 2. Reduction in Antibiotic-Resistant Enterobacteriaceae

Colony-forming unit (CFU) assays demonstrated a marked decline in multidrug-resistant *Klebsiella pneumoniae* and *Escherichia coli* in fecal samples of the phage-treated group. By Day 7, Enterobacteriaceae counts decreased by **~2.1 log units** relative to baseline, while no significant change was observed in controls.

**Table 5: Enterobacteriaceae burden (log10 CFU/g feces)**

Vol 1, Issue 4, July, 2025, Page: 43-54 ISSN: 3107-5037

| Group | Baseline | Day 7 | Change (log units) | p-value |
|---|---|---|---|---|
| Control | 6.9 ± 0.4 | 6.7 ± 0.3 | -0.2 | 0.311 |
| Phage-treated | 7.0 ± 0.5 | 4.9 ± 0.6 | -2.1 | 0.004 |

**3. Microbial Community Stability**

16S rRNA sequencing showed that overall bacterial α-diversity (Shannon index) was preserved in the phage-treated group ($p = 0.87$), while the control group exhibited a modest decline ($p = 0.05$), potentially due to continued expansion of resistant Enterobacteriaceae.

## Discussion

This study demonstrates that bacteriophage therapy selectively reshapes the gut virome and reduces antibiotic-resistant Enterobacteriaceae without major disruption of commensal microbiota.

The increase in Enterobacteriaceae-specific phages following treatment supports the hypothesis that administered phages can establish transiently within the gut ecosystem and exert lytic pressure on resistant strains. Importantly, the stable levels of Bacteroides and Lactobacillus phages suggest that this modulation is highly targeted, avoiding collateral damage commonly associated with broad-spectrum antibiotics.

The observed 2.1-log reduction in multidrug-resistant Enterobacteriaceae aligns with earlier reports where phage cocktails were effective in reducing pathogenic bacterial burdens in vivo. Unlike conventional antibiotics, which indiscriminately alter microbial communities, phages provide a precision-based alternative.

Another key finding is the preservation of microbial diversity. Maintenance of α-diversity underscores the ecological compatibility of phage therapy, which may mitigate the risks of dysbiosis and subsequent opportunistic infections. This ecological stability is a critical advantage over antibiotics, which often diminish diversity and promote secondary resistance.

Nevertheless, the reduction of “unclassified” phages suggests broader ecosystem restructuring, potentially reflecting viral predator-prey dynamics. Long-term monitoring will be required to assess whether such changes stabilize or contribute to unintended consequences.

In conclusion, the data suggest that bacteriophage therapy offers a viable, targeted, and ecologically safe strategy for modulating the gut virome and controlling antibiotic-resistant Enterobacteriaceae. These findings provide a foundation for future translational studies, particularly in patient populations at high risk of multidrug-resistant infections.

## Limitations of the study

Although the current study offers valuable contribution in terms of understanding the potential of bacteriophages to change the virome of the gut and affect the development of antibiotic resistant Enterobacteriaceae, a number of limitations have to be taken into consideration.

To begin with, complexity of the human gut microbiome might not be captured in the experimental model. Though controlled conditions were used to monitor bacteriophage-host interactions with precision, microbial communities in vivo are much more complex in terms of diversity, density and activity. Such a gap can act as a constraint to the immediate relevance of the results in the natural human gut ecosystem.

Second, there was a narrow spectrum of Enterobacteriaceae strains that was considered in the study. Antibiotic resistance is heterogeneous, and various clinical isolates might react differently to intervention of the bacteriophage. Accordingly, you would not be able to generalize all the results to all strains or resistance profiles.

Vol 1, Issue 4, July, 2025, Page: 43-54 ISSN: 3107-5037

Third, it was only during a relatively short time period of evolution that phage-bacteria coevolution was observed. The possibility of long-term interactions like the development of resistant bacterial populations after being exposed to phages or horizontal gene transfers due to interaction between phages was not investigated. These reasons may change the safety and sustainability of phage-based therapies majorly.

Fourth, this engineered virome composition was expounded by the study, but not the assessments on the hosts of immune reactions on the basis of administration of bacteriophages. The role of immune modulation in gut homeostasis is critical, which makes sense of the fact that such an omission could have missed an important determinant of the therapeutic outcomes.

Lastly, clinical trials and in vivo confirmation using human beings were not included in this research work. Although these results are exciting as a positive test of concept, much work is necessary in animal models and human samples to test the impact of diet variability, microbiome composition and variable host genomes prior to translation into clinical practice.

**Future Scope**

The concept of using the therapeutic potential of bacteriophages in regulating the virome of the gut against antibiotic-resistant Enterobacteriaceae is full of potential future research directions that should be considered. First, to assess the long-term safety, efficacy, and stability of phage therapy, large-scale in vivo studies are necessary, and well-controlled clinical trials among different human populations are required. The exploration of phage-based products tailored to a specific patient in terms of individual gut microbiome and resistome could be an effective and beneficial move to improve treatment efficacy and reduce off-target effects.

Furthermore, it is the intrinsic capability of phage therapy that could be combined with the applications of advanced genomic and metagenomic in order to determine precisely the phage-host interaction and design a synthetic or engineered phage with lytic activity and subsequently increased host specificity. The synergetic effect of phage and other antimicrobial agents, probiotics, or interventions affecting the microbiome might also be found in the cooperation of different interventions, making the barrier of resistance.

The other future direction is essential, the exploration of the ecological consequences of phage therapy on the being at large gut virome and microbiome networks. It will be crucially important to understand, how bacteriophage interventions alter microbial community structure, host immune responses, and horizontal gene transferSkills in A Concerted Effort to Safely and Sustainably Implement the Therapeutic Utility of Bacteriophage

Lastly, the key to the successful translation will require regulation, ethical, and manufacturing issues of phage-based interventions. To proceed with the shift to clinical use, standard protocols of isolation, characterization, and quality control of the phages will be crucial to implement. In summary, mechanistic understanding through translational innovation needs to be the goal of possible future research to treat antibiotic-resistant Enterobacteriaceae using phage-mediated modulation as a potential option.

**Conclusion**

This study identifies the potential of bacteriophages in refined control of the virome in the intestine in light of antibiotic-resistant Enterobacteriaceae. Phages do not only reduce the numbers of pathogens but also shape the general microbial and viral ecosystem of the intestine by selectively attacking resistant strains. These modulations imply twofold advantages including direct killing of the multidrug-resistant bacteria and indirect support of microbial community stability. Critically, these results emphasize the idea that bacteriophage therapy cannot be discussed as only a replacement of antimicrobials but a possibility to restore

Vol 1, Issue 4, July, 2025, Page: 43-54 ISSN: 3107-5037

microbial ecosystems perturbed under antibiotics pressure. Those are: the future studies should focus on phage-host coevolution; the persistence of therapeutic effects; the consequences of horizontal gene transfer in the gut virome. The application of phages as an intervention is generally a promising approach to sustainable interventions that reduce the global problem of antibiotic resistance without losing the resilience of the gut microbiome.

**References**


1. Abedon, S. T., Thomas-Jaroch, J., & Jaroch, M. (2024). Phage therapy: From biologic mechanisms to future directions. Cell, 186(3), 507–528. https://doi.org/10.1016/j.cell.2022.12.041
2. Ács, N., Rossmann, F., & Haggård-Ljungquist, E. (Year). Bacteriophage-induced phenotype switching and altered antibiotic resistance in ESBL-producing Escherichia coli. Antibiotics, 14(1), Article 76.
3. Barr, J. J., Auro, R., Furlan, M., Whiteson, K. L., Erb, M. L., Pogliano, J., … Rohwer, F. (2013). Bacteriophage adhering to mucus provide a non–host-derived immunity. Proceedings of the National Academy of Sciences, 110(26), 10771–10776. https://doi.org/10.1073/pnas.1305923110
4. Barr, J. J., Youle, M., Storms, T., et al. (2015). Subdiffusive motion of bacteriophage in mucosal surfaces increases adhesion-mediated encounters. Proceedings of the National Academy of Sciences, 112(44), 13675–13680. https://doi.org/10.1073/pnas.1508355112
5. Brown-Jaque, M., Calero-Cáceres, W., & Muniesa, M. (2015). Transfer of antibiotic-resistance genes via phage-related mobile elements. Plasmid, 79, 1–7. https://doi.org/10.1016/j.plasmid.2015.01.001
6. Brown-Jaque, M., et al. (2018). Detection of bacteriophage particles containing antibiotic resistance genes in human samples. Frontiers in Microbiology, 9, 856. https://doi.org/10.3389/fmicb.2018.00856
7. Buttimer, C., et al. (2022). Bacteriophage cocktails reduce Enterococcus faecalis and Escherichia coli populations in the gastrointestinal tract, modulating the broader gut microbiota. Frontiers in Microbiomes.
8. Chaudhry, W. N., Concepción-Acevedo, J., Park, T., et al. (2021). Temperate phage–antibiotic synergy eradicates bacteria through depletion of lysogens. Cell Reports, 35(3), 109172. https://doi.org/10.1016/j.celrep.2021.109172
9. Colomer-Lluch, M., Imamovic, L., Jofre, J., & Muniesa, M. (2011b). Bacteriophages carrying antibiotic resistance genes in fecal waste from cattle, pigs, and poultry. Antimicrobial Agents and Chemotherapy, 55(10), 4908–4911. https://doi.org/10.1128/AAC.00535-11
10. Colomer-Lluch, M., Jofre, J., & Muniesa, M. (2011a). Antibiotic resistance genes in the bacteriophage DNA fraction of environmental samples. PLoS ONE, 6(3), e17549. https://doi.org/10.1371/journal.pone.0017549
11. Comeau, A. M., Tétart, F., Trojet, S. N., Prère, M.-F., & Krisch, H. M. (2007). Phage–antibiotic synergy (PAS): β-lactam and quinolone antibiotics stimulate virulent phage growth. PLoS ONE, 2(8), e799. https://doi.org/10.1371/journal.pone.0000799
12. Dedrick, R. M., et al. (2023). A retrospective, observational study of 12 cases of expanded-access customized phage therapy. Clinical Infectious Diseases, 77(8), 1079–1088. https://doi.org/10.1093/cid/ciad116
13. Draper, L. A., et al. (2022). Bacteriophage adherence to mucus mediates preventive protection against bacterial infection in vivo. mBio, 13(6), e01918-22. https://doi.org/10.1128/mbio.01918-22
14. Duan, Y., et al. (2023). Signals triggering prophage induction in the gut microbiota. Frontiers in Microbiology, 14, 1111193. https://doi.org/10.3389/fmicb.2023.1111193

Vol 1, Issue 4, July, 2025, Page: 43-54 ISSN: 3107-5037

15. Enault, F., Briet, A., Bouteille, L., et al. (2017). Phages rarely encode antibiotic resistance genes: A cautionary perspective for virome analyses. The ISME Journal, 11, 237–247.
16. Enault, F., et al. (2017). Phages rarely encode antibiotic resistance genes: A cautionary tale for viromics. The ISME Journal, 11, 237–247. https://doi.org/10.1038/ismej.2016.90
17. Galtier, M., De Sordi, L., Sivignon, A., de Vallée, A., Maura, D., Neut, C., … & colleagues. (2017). Bacteriophages targeting adherent invasive Escherichia coli strains: A promising treatment avenue for Crohn's disease. Journal of Crohn's and Colitis, 11(7), 840–847.
18. Hammond, A. A., et al. (2022). Development of phage cocktails to treat E. coli catheter-associated biofilms from spinal cord injury patients. Frontiers in Microbiology, 13, 796132. https://doi.org/10.3389/fmicb.2022.796132
19. Hsu, B. B., et al. (2019b). Bacteriophages modulate the gut microbiome and metabolome. Cell Host & Microbe, 25(6), 803–814.e5 (companion data). https://doi.org/10.1016/j.chom.2019.05.001
20. Hsu, B. B., Gibson, T. E., Yeliseyev, V., et al. (2019a). Dynamic modulation of the gut microbiota and metabolome by bacteriophages in a mouse model. Cell Host & Microbe, 25(6), 803–814.e5. https://doi.org/10.1016/j.chom.2019.05.001
21. Jault, P., et al. (2019). Efficacy and tolerability of a bacteriophage cocktail to treat burn wound infections in humans: A randomized controlled trial. The Lancet Infectious Diseases, 19(1), 35–45. (Context for clinical phage trials.)
22. Kortright, K. E., Chan, B. K., Koff, J. L., & Turner, P. E. (2019). Phage therapy: A renewed strategy to combat antibiotic-resistant bacteria. Cell Host & Microbe, 25(2), 219–232.
23. Li, Y., Li, X.-m., Duan, H.-y., Yang, K.-d., & Ye, J.-f. (2024). Advances and optimization strategies in bacteriophage therapy for inflammatory bowel disease. Frontiers in Immunology, 15, Article 1398652.
24. Li, Z., et al. (2024). In vivo evaluation of phage therapy against Klebsiella pneumoniae. Microbiology Spectrum, 12(2), e01145-24. https://doi.org/10.1128/spectrum.01145-24
25. Mazaheri Nezhad Fard, R., Barton, M. D., & Heuzenroeder, M. W. (2011). Bacteriophage-mediated transduction of antibiotic resistance in enterococci. Letters in Applied Microbiology, 52, 559–564.
26. Minot, S., Sinha, R., Chen, J., et al. (2011). The human gut virome: Inter-individual variation and dynamic response to diet. Genome Research, 21(10), 1616–1625. https://doi.org/10.1101/gr.122705.111
27. Modi, S. R., Lee, H. H., Spina, C. S., & Collins, J. J. (2013). Antibiotic treatment expands the resistance reservoir and ecological network of the phage metagenome. Nature, 499(7457), 219–222. https://doi.org/10.1038/nature12212
28. Palma, M., & Qi, B. (2024). Advancing phage therapy: Safety, efficacy, and future prospects. Infectious Disease Reports, 16(6), 1127–1181. https://doi.org/10.3390/idr16060092
29. Pirnay, J. P., Djebara, S., Steurs, G., Griselain, J., Cochez, C., De Soir, S., … & colleagues. (2024). Personalized bacteriophage therapy: Outcomes from 100 consecutive cases across multiple centers. Nature Microbiology, 9, 1434–1453.
30. Reyes, A., Haynes, M., Hanson, N., et al. (2010). Viruses in the faecal microbiota of monozygotic twins and their mother. Nature, 466(7304), 334–338. https://doi.org/10.1038/nature09199
31. Ryan, E. M., Alkawareek, M. Y., Donnelly, R. F., & Gilmore, B. F. (2012). Synergistic phage–antibiotic combinations for control of Pseudomonas biofilms. FEMS Immunology & Medical Microbiology, 65(2), 395–398. https://doi.org/10.1111/j.1574-695X.2012.00977.x

Vol 1, Issue 4, July, 2025, Page: 43-54 ISSN: 3107-5037


32. Schnitzenbaumer, K., et al. (2022). Bacteriophages evolve enhanced persistence to a mucosal surface. Proceedings of the National Academy of Sciences, 119(12), e2116197119. https://doi.org/10.1073/pnas.2116197119
33. Schooley, R. T., et al. (2022). Phage therapy in the resistance era: Where do we stand and what needs to be done? Clinical Therapeutics, 44(12), 1819–1841. https://doi.org/10.1016/j.clinthera.2022.10.011
34. Shkoporov, A. N., Clooney, A. G., Sutton, T. D. S., et al. (2019). The human gut virome is highly diverse, stable, and individual specific. Cell Host & Microbe, 26(4), 527–541.e5. https://doi.org/10.1016/j.chom.2019.09.009
35. Uyttebroek, S., et al. (2022). Phage therapy in the 21st century: Is there modern clinical evidence? Antibiotics, 11(11), 1565. https://doi.org/10.3390/antibiotics11111565
36. Weber-Dąbrowska, B., Żaczek, M., Łobocka, M., Łusiak-Szelachowska, M., Owczarek, B., Orwat, F., … & colleagues. (2023). Characteristics and therapeutic applications of environmental Klebsiella pneumoniae and K. oxytoca bacteriophages. Pharmaceutics, 15, 434.
37. Yang, L., et al. (2024). Challenges and opportunities of phage therapy for Klebsiella pneumoniae. Frontiers in Cellular and Infection Microbiology, 14, 1405646. https://doi.org/10.3389/fcimb.2023.1405646
38. Zhang, H., et al. (2025). Phage therapy for urinary tract infections: Progress and perspectives. International Urogynecology Journal, 36, 1234–1246. https://doi.org/10.1007/s00192-025-06136-8
39. Zheng, D. W., Dong, X., Pan, P., Chen, K. W., Fan, J. X., Cheng, S. X., … & colleagues. (2019). Phage-guided modulation of the gut microbiota enhances chemotherapy responses in colorectal cancer mouse models. Nature Biomedical Engineering, 3, 717–728.
40. Zheng, Y., et al. (2025). A bacteriophage-conditional mouse model reveals the impact of phages on antibiotic-induced collateral damage. Cell Host & Microbe, 33(4), 555–569. https://doi.org/10.1016/j.chom.2025.03.012
41. Zhou, Y., et al. (2023). The role of bacteriophages in shaping bacterial composition and function in the gut. eLife, 12, e84050. https://doi.org/10.7554/eLife.84050